These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24638002)

  • 21. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
    Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
    Procopio G; Verzoni E; De Braud F
    Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
    [No Abstract]   [Full Text] [Related]  

  • 23. [mTOR inhibitors].
    Oya M
    Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian target of rapamycin (mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?
    Rodriguez-Vida A; Chau NM; Chowdhury S
    BJU Int; 2014 Mar; 113(3):350-1. PubMed ID: 24528875
    [No Abstract]   [Full Text] [Related]  

  • 25. [Management of side effects of everolimus treatment for metastatic renal cell carcinoma].
    Mikami K; Hongo F; Miki T
    Hinyokika Kiyo; 2012 Nov; 58(11):647-50. PubMed ID: 23254794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of everolimus in renal cell cancer.
    Amato R; Stepankiw M
    Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
    Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
    J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active tuberculosis during temsirolimus and bevacizumab treatment.
    Lin CC; Wang JY; Pu YS
    J Clin Oncol; 2013 Jan; 31(2):e18-20. PubMed ID: 23169507
    [No Abstract]   [Full Text] [Related]  

  • 30. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract]   [Full Text] [Related]  

  • 31. Lingual angioedema associated with everolimus.
    Mackenzie M; Wood LA
    Acta Oncol; 2010; 49(1):107-9. PubMed ID: 20100146
    [No Abstract]   [Full Text] [Related]  

  • 32. Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus.
    Creel P; Moldawer NP
    Oncol Nurs Forum; 2011 Mar; 38(2):125-8. PubMed ID: 21356651
    [No Abstract]   [Full Text] [Related]  

  • 33. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
    Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
    [No Abstract]   [Full Text] [Related]  

  • 34. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus and pazopanib: two new drugs for renal cell cancer.
    Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
    [No Abstract]   [Full Text] [Related]  

  • 36. Spontaneous resolution of Pneumocystis jirovecii pneumonia on high-resolution computed tomography in a patient with renal cell carcinoma.
    Tanaka Y; Saraya T; Kurai D; Ishii H; Takizawa H; Goto H
    Am J Case Rep; 2014 Nov; 15():496-500. PubMed ID: 25396336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].
    Gennigens C; Sautois B; Jerusalem G
    Rev Med Liege; 2010 Apr; 65(4):212-6. PubMed ID: 20499824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
    J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal cell carcinoma management and therapies in 2010].
    Albouy B; Gross Goupil M; Escudier B; Massard C
    Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.